Dermapharm: Muted Growth Outlook and Arkopharma Uncertainty Underpin Hold Rating

In a report released today, Fabian Piasta from Jefferies maintained a Hold rating on Dermapharm Holding SE, with a price target of €34.00.

Fabian Piasta has given his Hold rating due to a combination of factors around Dermapharm’s muted growth outlook and only marginal profitability gains. Management’s guidance for 2026 signals low single‑digit revenue expansion of roughly 1–5% and an almost flat uptick in margins, suggesting limited upside versus current expectations and justifying a neutral stance.

The group’s organic growth in branded pharmaceuticals and new product launches offers some support, but caution around Arkopharma and continued sales reductions in parallel imports weigh on the overall growth profile. While operational measures and the build‑out of a non‑pharma unit may gradually restore low single‑digit growth and Arkopharma could become a key upside catalyst, the timing and scale remain uncertain, leading Piasta to maintain a Hold recommendation rather than turn more positive at this stage.